NEPHROS INC (NEPH)

US6406714005 - Common Stock

1.54  +0.08 (+5.48%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NEPH. NEPH was compared to 131 industry peers in the Machinery industry. The financial health of NEPH is average, but there are quite some concerns on its profitability. NEPH is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

NEPH had negative earnings in the past year.
NEPH had a negative operating cash flow in the past year.
In the past 5 years NEPH always reported negative net income.
NEPH had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

NEPH's Return On Assets of -8.94% is on the low side compared to the rest of the industry. NEPH is outperformed by 77.17% of its industry peers.
The Return On Equity of NEPH (-11.37%) is worse than 73.23% of its industry peers.
Industry RankSector Rank
ROA -8.94%
ROE -11.37%
ROIC N/A
ROA(3y)-34.55%
ROA(5y)-31.77%
ROE(3y)-62%
ROE(5y)-59.43%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 61.04%, NEPH belongs to the best of the industry, outperforming 98.43% of the companies in the same industry.
In the last couple of years the Gross Margin of NEPH has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NEPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.96%
GM growth 5Y0.97%

More info and screens

5

2. Health

2.1 Basic Checks

NEPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NEPH has been increased compared to 1 year ago.
Compared to 5 years ago, NEPH has more shares outstanding
NEPH has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -13.37, we must say that NEPH is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -13.37, NEPH is doing worse than 96.06% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that NEPH is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, NEPH belongs to the top of the industry, outperforming 84.25% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.37
ROIC/WACCN/A
WACC9.47%

2.3 Liquidity

A Current Ratio of 6.95 indicates that NEPH has no problem at all paying its short term obligations.
The Current ratio of NEPH (6.95) is better than 95.28% of its industry peers.
NEPH has a Quick Ratio of 4.02. This indicates that NEPH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NEPH (4.02) is better than 92.91% of its industry peers.
Industry RankSector Rank
Current Ratio 6.95
Quick Ratio 4.02

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.63% over the past year.
Looking at the last year, NEPH shows a decrease in Revenue. The Revenue has decreased by -0.03% in the last year.
NEPH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.13% yearly.
EPS 1Y (TTM)52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.48%
Revenue growth 5Y20.13%
Sales Q2Q%-5.99%

3.2 Future

The Earnings Per Share is expected to grow by 35.29% on average over the next years. This is a very strong growth
Based on estimates for the next years, NEPH will show a small growth in Revenue. The Revenue will grow by 4.77% on average per year.
EPS Next Y72.8%
EPS Next 2Y46.15%
EPS Next 3Y35.29%
EPS Next 5YN/A
Revenue Next Year-6.32%
Revenue Next 2Y1.11%
Revenue Next 3Y4.77%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NEPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
NEPH is valuated quite expensively with a Price/Forward Earnings ratio of 75.49.
Based on the Price/Forward Earnings ratio, NEPH is valued a bit more expensive than 68.50% of the companies in the same industry.
NEPH's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.69.
Industry RankSector Rank
PE N/A
Fwd PE 75.49

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NEPH's earnings are expected to grow with 35.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.15%
EPS Next 3Y35.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NEPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEPHROS INC

NASDAQ:NEPH (1/3/2025, 8:00:01 PM)

1.54

+0.08 (+5.48%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners40.98%
Inst Owner Change-0.82%
Ins Owners11.74%
Ins Owner Change0%
Market Cap16.23M
Analysts82.5
Price Target5.1 (231.17%)
Short Float %0.05%
Short Ratio0.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.98%
Min EPS beat(2)-96.08%
Max EPS beat(2)198.04%
EPS beat(4)2
Avg EPS beat(4)4.41%
Min EPS beat(4)-135.29%
Max EPS beat(4)198.04%
EPS beat(8)4
Avg EPS beat(8)2.29%
EPS beat(12)6
Avg EPS beat(12)-18.18%
EPS beat(16)8
Avg EPS beat(16)-12.25%
Revenue beat(2)0
Avg Revenue beat(2)-9.42%
Min Revenue beat(2)-17.42%
Max Revenue beat(2)-1.43%
Revenue beat(4)0
Avg Revenue beat(4)-10.68%
Min Revenue beat(4)-17.42%
Max Revenue beat(4)-1.43%
Revenue beat(8)2
Avg Revenue beat(8)-4.18%
Revenue beat(12)3
Avg Revenue beat(12)-6.31%
Revenue beat(16)4
Avg Revenue beat(16)-5.24%
PT rev (1m)0%
PT rev (3m)5.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 75.49
P/S 1.2
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 2.38
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)0.02
Fwd EY1.32%
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS1.29
BVpS0.78
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.94%
ROE -11.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.04%
FCFM N/A
ROA(3y)-34.55%
ROA(5y)-31.77%
ROE(3y)-62%
ROE(5y)-59.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.96%
GM growth 5Y0.97%
F-Score4
Asset Turnover1.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.33%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.95
Quick Ratio 4.02
Altman-Z -13.37
F-Score4
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)30.35%
Cap/Depr(5y)42.07%
Cap/Sales(3y)0.77%
Cap/Sales(5y)1.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y72.8%
EPS Next 2Y46.15%
EPS Next 3Y35.29%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.48%
Revenue growth 5Y20.13%
Sales Q2Q%-5.99%
Revenue Next Year-6.32%
Revenue Next 2Y1.11%
Revenue Next 3Y4.77%
Revenue Next 5YN/A
EBIT growth 1Y41.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.67%
OCF growth 3YN/A
OCF growth 5YN/A